Bethesda, March 29, 2016 -- India Globalization Capital, Inc. (NYSE MKT: IGC), announced that it has raised $300,000 in a private placement. 681,818 shares of newly issued unregistered common stock were sold at March 23, 2016’s closing price of $0.44 per share. After fees and expenses, the net proceeds to IGC are approximately $290,000. The net proceeds from the offering are for working capital. The offering closed on March 23, 2016, subject to customary closing conditions, including approval by the NYSE.
This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any state.
About IGC:
In the United States, we develop phytocannabinoid-based therapies and build state-of-the art farming facilities that we can eventually use to grow and extract pharmaceutical grade phytocannabinoids. Longer term, we expect to position the company to be a leading provider of cannabinoid based Active Pharmaceutical Ingredients (“API”). Internationally, IGC engages in leasing, trading and managing infrastructure projects. IGC has several patent filings for the indications of Pain, Medical Refractory Epilepsy and Cachexia using cannabinoids. We are based in Bethesda, Maryland.
Our website: www.igcinc.us. Twitter @IGCIR
Forward-looking Statements:
Some of the statements contained in this press release that are not historical facts constitute forward- looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "intends," "potential," "proposed," or the negative of those terms. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond IGC's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, our acquisition and diversification strategy, our competitive environment, and governmental, regulatory, political, economic, legal and social conditions. Except as required by federal securities laws, IGC undertakes no obligation to publicly update any forward- looking statements, whether as a result of new information, future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward- looking statements have been discussed in greater detail in IGC's Form 10- K for fiscal year ended March 31, 2015, and in subsequent reports filed with the U.S. SEC.
Claudia Grimaldi Phone: 301-983-0998


Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 



